<DOC>
	<DOCNO>NCT00844727</DOCNO>
	<brief_summary>Preliminary data indicate protective effect development duodenal polyp coxib treatment . The hypothesis present study normal therapy dose rofecoxib 1 year would stop reverse development premalignant adenomatous lesion duodenal mucosa FAP patient .</brief_summary>
	<brief_title>Coxib-inhibition Duodenal Polyp Growth FAP</brief_title>
	<detailed_description />
	<mesh_term>Rofecoxib</mesh_term>
	<criteria>FAP patient previous colectomy confirm polyposis Pregnancy Malignancy NSAID hypersensitivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>